Virtu Financial LLC purchased a new stake in ObsEva SA (NASDAQ:OBSV) in the fourth quarter, Holdings Channel reports. The institutional investor purchased 79,535 shares of the company’s stock, valued at approximately $165,000.
Other hedge funds and other institutional investors have also modified their holdings of the company. Morgan Stanley lifted its stake in ObsEva by 299.8% during the fourth quarter. Morgan Stanley now owns 1,909,114 shares of the company’s stock valued at $3,971,000 after buying an additional 1,431,647 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in ObsEva during the fourth quarter valued at about $1,250,000. Credit Suisse AG lifted its stake in ObsEva by 1.5% during the fourth quarter. Credit Suisse AG now owns 596,564 shares of the company’s stock valued at $1,241,000 after buying an additional 8,549 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in ObsEva by 39.1% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 356,215 shares of the company’s stock valued at $741,000 after buying an additional 100,220 shares in the last quarter. Finally, Barclays PLC lifted its stake in ObsEva by 310.9% during the fourth quarter. Barclays PLC now owns 173,835 shares of the company’s stock valued at $361,000 after buying an additional 131,524 shares in the last quarter. 52.74% of the stock is owned by institutional investors.
OBSV has been the subject of a number of analyst reports. HC Wainwright reduced their price objective on shares of ObsEva from $23.00 to $17.00 and set a “buy” rating for the company in a research note on Monday, January 4th. Wedbush reissued a “buy” rating and issued a $28.00 price target on shares of ObsEva in a research report on Tuesday, January 12th. SVB Leerink increased their price target on shares of ObsEva from $4.00 to $5.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 12th. Finally, Zacks Investment Research raised shares of ObsEva from a “sell” rating to a “hold” rating in a research report on Tuesday, January 12th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $10.21.
ObsEva (NASDAQ:OBSV) last released its quarterly earnings data on Thursday, March 4th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.12. As a group, sell-side analysts forecast that ObsEva SA will post -1.78 earnings per share for the current fiscal year.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.
Want to see what other hedge funds are holding OBSV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ObsEva SA (NASDAQ:OBSV).
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.